Is BCRX or BKHA more undervalued in 2026?

CirclFi compares BioCryst Pharmaceuticals, Inc. (BCRX) and Black Hawk Acquisition Corporat (BKHA) using 13 institutional-grade valuation models. BCRX has a Quality of Company score of 6.9/10 while BKHA scores 4.1/10.

Which is a better buy — BCRX or BKHA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BCRX and BKHA valuations compare?

BCRX at $8.91 and BKHA at $11.73 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BCRX vs BKHA Valuation Comparison 2026 — Intrinsic Value Analysis

BCRX

Biological Products, (No Diagnostic Substances)

BioCryst Pharmaceuticals, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$8.91

Last close

Models

12/13

Active

BKHA

Biological Products, (No Diagnostic Substances)

Black Hawk Acquisition Corporat

Quality

4.1

out of 10

Value Trap

—

Price

$11.73

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	BCRX Fair Value	BCRX Upside	BKHA Fair Value	BKHA Upside
Bayesian DCF	Intrinsic	$14.22	+66.7%	$1.67	-86.0%
Earnings Power Value	Intrinsic	$2.33	-74.2%	$2.18	-81.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BCRX vs BKHA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BCRX vs BKHA — Which Stock Is More Undervalued?

BCRX scores higher with a 6.9/10 quality rating vs BKHA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BioCryst Pharmaceuticals, Inc. (BCRX) and Black Hawk Acquisition Corporat (BKHA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BCRX currently trades at $8.91 with a QOC of 6.9/10, while BKHA trades at $11.73 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).